Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Non-phase study NCT07108166

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma…

📅 07 May 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT07108166
Start
2025-04-02
Completion
2026-08
ClinicaliQ Trial Snapshot
  • Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07108166.
  • COPD patients switching to heated tobacco showed improvements in cough, breathing, and lung function compared to continuing cigarettes.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test [6MWT]) after switching to THS compared to continuing to smoking cigarettes. Conditions: COPD, Smoking, Tobacco Use Interventions: Cigarette, THS Lead Sponsor: Philip Morris Products S.A. Planned Enrollment: 290 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 26 Mar 2026
Dupilumab is recommended for maintenance treatment of uncontrolled COPD only in patients with blood eosinophil count ≥400 cells/μL, as this biomarker predicts…
View guideline →
Guideline
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
Respiratory / COPD / Asthma · 25 Mar 2026
Confirm COPD diagnosis with spirometry showing post-bronchodilator FEV1/FVC ratio
View guideline →
Guideline
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Respiratory / COPD / Asthma · 25 Mar 2026
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Drug Science
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma
Respiratory / COPD / Asthma · 04 Apr 2026
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma is a clinically relevant Drug Science explainer. Bronchodilation in obstructive airway disease is achieved through…
Explore mechanism →
Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →